tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

CSPC Pharmaceutical Group Reports Revenue Decline Amid Industry Challenges

Story Highlights
CSPC Pharmaceutical Group Reports Revenue Decline Amid Industry Challenges

TipRanks Black Friday Sale

The latest update is out from CSPC Pharmaceutical Group ( (HK:1093) ).

CSPC Pharmaceutical Group reported a 12.3% decrease in total revenue and a 7.1% decline in reported profit for the first nine months of 2025 compared to the previous year. The finished drugs segment, which experienced a 17.2% revenue drop, was notably impacted by industry policies like centralized volume-based procurement and drug price adjustments. Despite these challenges, the company saw growth in bulk products and functional foods, indicating a shift in market dynamics.

The most recent analyst rating on (HK:1093) stock is a Hold with a HK$8.50 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is a company incorporated in Hong Kong, operating within the pharmaceutical industry. The company focuses on the production and sale of finished drugs, bulk products, and functional foods, with a significant emphasis on therapeutic areas such as the nervous system, oncology, and anti-infectives.

Average Trading Volume: 150,391,035

Technical Sentiment Signal: Buy

Current Market Cap: HK$90.53B

See more insights into 1093 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1